UK Markets closed

Global Synovial Sarcoma Pipeline Insights Report 2021 - Assess Challenges and Seek Opportunities that Could Influence R&D

·3-min read

Dublin, Dec. 16, 2021 (GLOBE NEWSWIRE) -- The "Synovial Sarcoma - Pipeline Insight, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.

This report provides comprehensive insights about 14+ companies and 14+ pipeline drugs in Synovial sarcoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Synovial sarcoma R&D. The therapies under development are focused on novel approaches to treat/improve Synovial sarcoma.

Emerging Drugs Chapters

This segment of the Synovial sarcoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Emerging Drugs

ADP-A2M4: Adaptimmune

ADP-A2M4 (MAGE-A4) SPEAR T-cell therapy is directed to a member of the MAGE family of cancer testis antigen expressed in a number of solid tumor cell types. The MAGE- A4 antigen is among the most commonly expressed cancer-testis antigens. Currently, it is in Phase II stage of clinical trial evaluation to treat Synovial Sarcoma.

Catequentinib: Advenchen Laboratories

Catequentinib (formerly anlotinib) is an orally bioavailable kinase inhibitor of receptor tyrosine, being jointly developed by Advenchen Laboratories and Jiangsu Chia Tai Tianqing Pharmaceutical. Currently, it is in Phase III stage of clinical trial evaluation to treat Synovial Sarcoma.

Therapeutic Assessment

This segment of the report provides insights about the different Synovial sarcoma drugs segregated based on following parameters that define the scope of the report, such as:

Major Players

There are approx. 14+ key companies which are developing the therapies for Synovial sarcoma. The companies which have their Synovial sarcoma drug candidates in the most advanced stage, i.e. phase II include, Adaptimmune.

Pipeline Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Synovial sarcoma therapeutic drugs key players involved in developing key drugs.

Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Synovial sarcoma drugs.

Key Questions Answered

  • How many companies are developing Synovial sarcoma drugs?

  • How many Synovial sarcoma drugs are developed by each company?

  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Synovial sarcoma?

  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Synovial sarcoma therapeutics?

  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

  • What are the clinical studies going on for Synovial sarcoma and their status?

  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • Adaptimmune

  • Advenchen Laboratories, LLC

  • Genentech

  • OncoTherapy Science, Inc.

  • Takara Bio

  • Eli Lilly and Company

  • Foghorn Therapeutics Inc.

  • Epizyme, Inc.

  • GlaxoSmithKline

  • Incyte Corporation

  • BioAtla, Inc.

  • Shenzhen BinDeBio Ltd.

  • Highlight Therapeutics

  • MediGene AG

  • C4 Therapeutics

Key Products

  • AL3818

  • ADP A2M4

  • CMB 305

  • OTSA101-DTPA

  • TBI-1301

  • Ramucirumab

  • FHD-609

  • Tazemetostat

  • NY-ESO-1(c259)T Cells

  • Itacitinib

  • CAB-AXL-ADC

  • BO-112

  • CFT 8634

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/ge05b

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting